Wendy Nagle
Family · Madera, CANPI 1265682033
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 216 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 12.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,388 and has fallen 51.0% since, to $680 in 2025. Among family clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 216 payments — averaging $25.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$667
- Livanova USA, Inc.$640
- Neurelis, Inc.$636
- PTC Therapeutics, Inc.$399
- Jazz Pharmaceuticals Inc.$263
- Zogenix Inc.$244
- plus $3K from 29 others
What the payments were for
- Food & beverage$5,406100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 25 | $667 |
| Livanova USA, Inc. | 26 | $640 |
| Neurelis, Inc. | 18 | $636 |
| PTC Therapeutics, Inc. | 21 | $399 |
| Jazz Pharmaceuticals Inc. | 11 | $263 |
| Zogenix Inc. | 8 | $244 |
| Biogen | 10 | $238 |
| Catalyst Pharmaceuticals, Inc. | 10 | $229 |
| Eisai Inc. | 13 | $226 |
| Ipsen Biopharmaceuticals, Inc | 7 | $180 |
| Genentech USA, Inc. | 6 | $162 |
| Sarepta Therapeutics, Inc. | 7 | $156 |
| Amneal Pharmaceuticals LLC | 6 | $146 |
| Alk-abello, Inc | 1 | $125 |
| Verrica Pharmaceuticals Inc. | 1 | $123 |
| NS Pharma, Inc. | 6 | $122 |
| Aquestive Therapeutics, Inc. | 6 | $117 |
| Supernus Pharmaceuticals, Inc. | 4 | $86 |
| ITF Therapeutics LLC | 4 | $83 |
| Immedica Pharma US, Inc. | 3 | $67 |
| Nobelpharma America, LLC | 3 | $59 |
| Argenx US, Inc. | 2 | $59 |
| Sumitomo Pharma America, Inc. | 3 | $54 |
| Novartis Gene Therapies, Inc. (fka Avexis, Inc.) | 2 | $45 |
| Aucta Pharmaceuticals, Inc. | 2 | $44 |
| Acadia Pharmaceuticals Inc | 2 | $40 |
| AbbVie | 1 | $33 |
| SK Life Science, Inc. | 1 | $32 |
| Piramal Critical Care | 1 | $23 |
| Novartis | 1 | $21 |
| Ultragenyx Pharmaceutical Inc. | 1 | $21 |
| Biocodex, Inc. | 1 | $20 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
| Biomarin Pharmaceutical Inc. | 1 | $15 |
| AstraZeneca | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VNS - Sentiva$125
- Nayzilam$125
- Fintepla$124
- YCANTH$123
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR$109
How this compares
$5,406 in reported general payments places this provider in the 95th percentile of 10,634 family providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clonazepam | 12 | $204 |
Paid to pharmacies, not to this prescriber.
Other family in Madera
- Lori RobertsonChino Hills$475K
- Annette ShonLos Angeles$406K
- Lisa HigginsHanford$311K
- Jennifer TougasBakersfield$302K
- Kim SchaferSacramento$288K
- Dawn MeyerSan Diego$270K
- Jennifer KangCerritos$255K
- Erin DwyerSan Diego$189K
- Phyllis CasonLos Angeles$187K
- Gabriel SchwartzSan Francisco$166K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.